title: Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
authors.affiliation: Department of Medicine (Plitt), Sinai Medical Center, New York, New York.
authors.forename: Anna
authors.initials: A
authors.lastname: Plitt
authors.affiliation: Department of Cardiovascular Medicine (Ezekowitz), Jefferson Medical College, Wynnewood, Pennsylvania.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ezekowitz
authors.affiliation: Department of Cardiology (De Caterina), Institute of Cardiology and Center of Excellence on Aging, "G. D'Annunzio" University, Chieti, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: De Caterina
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital (Nordio, Giugliano), Boston, Massachusetts.
authors.forename: Francesco
authors.initials: F
authors.lastname: Nordio
authors.affiliation: Department of Clinical Development (Peterson), Daiichi Sankyo Pharma Development, Edison, New Jersey.
authors.forename: Nancy
authors.initials: N
authors.lastname: Peterson
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital (Nordio, Giugliano), Boston, Massachusetts.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D001282:Atrial Flutter / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004554:Electric Countershock / Q000009:adverse effects; D065427:Factor Xa Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; D014859:Warfarin; C552171:edoxaban